Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort

Basit Öğe Kaydı
dc.authorid0000-0001-6826-7818
dc.authorid0000-0001-9636-4113
dc.contributor.authorMutlu, Yaşa Gül
dc.contributor.authorGüvenç, Birol
dc.contributor.authorSerin, İstemi
dc.contributor.authorBalık Aydın, Berrin
dc.contributor.authorAlacacıoğlu, İnci
dc.contributor.authorGüven, Serkan
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2023-03-16T11:32:44Z
dc.date.available2023-03-16T11:32:44Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractTreatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' perspective on TFR and factors that associated with willingness for tyrosine kinaz inhibitor (TKI) discontinuation from four different center in Turkey based on a national survey. Patients in our cohort had 7.8% awareness of TFR and after brief information willingness to attempt TFR has been reached to 58.9% in all population. Shorter disease duration was associated with enhanced willingness to attempt discontinuation in multivariate analyses (p=0.031). Most common patient related limitation for TKI discontinuation decision was anxiety about disease relaps and TKI resistance. Even disease relaps in TFR means molecular and detectable with close monitoring, patients still had considerable concerns about TKI discontinuation.
dc.identifier.citationMutlu, Y. G., Güvenç, B., Serin, İ., Balık Aydın, B., Alacacıoğlu, İ., Güven, S. ... Sevindik, Ö. G. (2022). Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort. Blood içinde (11490-11490. ss.). https://dx.doi.org/10.1182/blood-2022-165732
dc.identifier.doi10.1182/blood-2022-165732
dc.identifier.endpage11490
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.issueSupplement: 1
dc.identifier.startpage11490
dc.identifier.urihttps://dx.doi.org/10.1182/blood-2022-165732
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10623
dc.identifier.volume140
dc.identifier.wos000893230304268en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorBalık Aydın, Berrin
dc.institutionauthorSevindik, Ömür Gökmen
dc.language.isoen
dc.publisherAmerican Society of Hematology
dc.relation.ispartofBlooden_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTurkish Multicenter Cohort
dc.subjectCML
dc.subjectFree Remission
dc.titleAssesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Aydin-Berrin-2022.pdf
Boyut:
198.93 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Bildiri Koleksiyonu
Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu